The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
Abstract
PURPOSE: To compare the efficacy and tolerability of anastrozole (Arimidex; AstraZeneca, Wilmington, DE, and Macclesfield, United Kingdom) with that of tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal women. PATIENTS AND METHODS: This randomized, double-blind, multicenter study evaluated the efficacy of anastrozole 1 mg once daily relative to tamoxifen 20 mg once daily in patients with tumors that were hormone receptor–positive or of unknown receptor status who were eligible for endocrine therapy. The primary end points were time to progression (TTP), objective response (OR), and tolerability. RESULTS: A total of 668 patients (340 in the anastrozole arm and 328 in the tamoxifen arm) were randomized to treatment and followed-up for a median of 19 months. Median TTP was similar for both treatments (8.2 months in patients who received anastrozole and 8.3 months in patients who received tamoxifen). The tamoxifen:anastrozole hazards ratio was 0.99 (lower one-sided 95% confidence limit, 0.86), demonstrating that anastrozole was at least equivalent to tamoxifen. Anastrozole was also as effective as tamoxifen in terms of OR (32.9% of anastrozole and 32.6% of tamoxifen patients achieved a complete response [CR] or partial response [PR]). Clinical benefit (CR + PR + stabilization of ≥ 24 weeks) rates were 56.2% and 55.5% for patients receiving anastrozole and tamoxifen, respectively. Both treatments were well tolerated. However, incidences of thromboembolic events and vaginal bleeding were reported in fewer patients treated with anastrozole than with tamoxifen (4.8% v 7.3% [thromboembolic events] and 1.2% v 2.4% [vaginal bleeding], respectively). CONCLUSION: Anastrozole satisfied the predefined criteria for equivalence to tamoxifen. Together with the lower observed incidence of thromboembolic events and vaginal bleeding, these findings indicate that anastrozole should be considered as first-line therapy for postmenopausal women with ABC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Boring, C. C., Squires, T. S., & Tong, T. (1993) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.43.1.7 · Cited by 966
Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 638
Hayward, J. L., Carbone, P. P., Heuson, J.-C., Kumaoka, S., Segaloff, A., & Rubens, R. D. (1977) · Cancer · doi:10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f · Cited by 623
Cancer in the European community and its member states
Møller Jensen, O., Estève, J., Møller, H., & Renard, H. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90278-2 · Cited by 455
Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., BLOMQVIST, C. P., Vogel, C. L., EIERMANN, W., Wolter, J. M., Steinberg, M., Webster, A., et al. (1998) · PubMed · Cited by 417
Self-citationGeisler, J., King, N., Dowsett, M., Ottestad, L., Lundgren, S., Walton, P., Kormeset, P., & Lønning, P. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.531 · Cited by 336
Rutqvist, L. E., & Anders Mattsson for the Stockholm Breast Cancer Study Group (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.17.1398 · Cited by 334
Love, R. R., Wiebe, D. A., Feyzi, J. M., Newcomb, P. A., & Chappell, R. J. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.20.1534 · Cited by 278
Effect of Tamoxifen on Lumbar Spine Bone Mineral Density in Postmenopausal Women After 5 Years
Love, R. R. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.22.2585 · Cited by 199
Arimidex Study Group, Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C. P., Vogel, C. L., Eiermann, W., Wolter, J. M., Steinberg, M., et al. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980915)83:6<1142::aid-cncr13>3.0.co;2-5 · Cited by 174
Self-citationTamoxifen Flare in Advanced Breast Cancer
Plotkin, D. (1978) · JAMA · doi:10.1001/jama.1978.03290240044022 · Cited by 142
Reddel, R. R., & Sutherland, R. L. (1984) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(84)90062-2 · Cited by 125
Buzdar, A. U., Smith, R. A., Vogel, C. L., Bonomi, P., Keller, A. M., Favis, G., Mulagha, M. T., Cooper, J., & for the Multi-Institutional Trialist Collaborative Study Group (1996) · Cancer · Cited by 118
Howell, A., Mackintosh, J., Jones, M., Redford, J., Wagstaff, J., & Sellwood, R. A. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90046-6 · Cited by 106
Thurlimann, B. J. K., Beretta, K., Bacchi, M., Castiglione‐Gertsch, M., Goldhirsch, A., Jungi, W. F., Cavalli, F., Senn, H.-J., Fey, M. F., & Löhnert, T. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010635 · Cited by 95
Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications
Brodie, A. M. H., & Njar, V. C. O. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00022-3 · Cited by 88
Antioestrogens in the management of hormone-dependent cancer
Litherland, S. A., & Jackson, I. M. (1988) · Cancer Treatment Reviews · doi:10.1016/0305-7372(88)90002-3 · Cited by 83
Robertson, J. F. R., Williams, M. R., Todd, J. H., Nicholson, R. I., Morgan, D. A. L., & Blamey, R. W. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90259-9 · Cited by 72
Self-citationRobertson, J. F. R., Howell, A., Buzdar, A. U., von Euler, M., & Lee, D. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006391902868 · Cited by 40
Self-citation
Cited by
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Metadata
- Authors
- Bonneterre, J., Thürlimann, B., Robertson, J. F. R., Krzakowski, M., Mauriac, L., Koralewski, P., Vergote, I., Webster, A., Steinberg, M., & von Euler, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-11-15
- Volume
- 18
- Issue
- 22
- Pages
- 3748-3757
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2132846837
- Cited by
- 842
- References
- 21
- FWCI
- 26.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.